Indication: Squamous Cell Carcinoma
Phase III Study of Buparlisib (AN2025) Plus Paclitaxel Compared to Paclitaxel Alone in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sub-indication: Head and Neck Cancer
Study Type: Drug Study
Principal Investigator: Jaspreet Grewal, M.D.Norton Cancer Institute
Sponsor: Sponsor: Adlai Nortye USA Inc
Learn more at ClinicalTrials.gov
Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org